Rapport Therapeutics

Visit Website

Clinical-stage biotech building precision small-molecule medicines for neurological and psychiatric disorders using receptor-associated protein (RAP) biology, spun out of Third Rock Ventures and Johnson & Johnson Innovation.

Headquarters

Boston, USA / San Diego, USA

Year Founded

2023

Founders

David Bredt (CSO), Abe Ceesay (CEO)

Country

United States

Financial Information

Funding Stage

Series B (publicly traded, Nasdaq: RAPP)

Recent Funding

$250M

Funding By

Third Rock Ventures, ARCH Venture Partners, Johnson & Johnson Innovation

Core Technology

Receptor-associated protein (RAP) targeting platform

Product Type

Drug

Pipeline Stage (Very Important)

Phase III

Regulatory Status

IND Filed: Yes
FDA/EMA Status: FDA Clinical
Clinical Trial Registration: Phase 3 FOCUS 1/FOCUS 2 (focal onset seizures)
Patents / IP Status: Filed

Partnerships

Pharma Collaborations

Janssen (J&J) Innovation

Academic / Hospital Tie-ups

Boston and San Diego research institutions

CRO/CDMO Partnerships

None disclosed

Market & Differentiation

First precision medicines targeting RAPs with unprecedented neuroanatomical specificity